+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07309952

Phase II Study of Neoadjuvant Stereotactic Body Radiotherapy Followed by Sintilimab and Chemotherapy for Treating Locally Advanced Non-Small Cell Lung Cancer with N3 Lymph Node Involvement

Led by Yang Hong · Updated on 2026-04-30

28

Participants Needed

1

Research Sites

261 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach for patients with locally advanced non-small cell lung cancer NSCLC that has spread to lymph nodes on the opposite side of the chest, known as N3 lymph node involvement. This Phase II clinical trial focuses on patients aged 18 to 75 years with untreated, potentially resectable stage IIIB-IIIC NSCLC. The study aims to assess whether the treatment can reduce cancer in the contralateral mediastinal lymph node and increase the chance for curative surgery, while also monitoring safety and other outcomes. The treatment plan involves stereotactic body radiation therapy SBRT targeting the primary lung tumor in three sessions over about three days. Within a week after SBRT, participants receive two cycles of sintilimab, an immunotherapy drug, combined with platinum-based chemotherapy. Depending on cancer type, chemotherapy drugs include paclitaxel or pemetrexed, along with carboplatin. After neoadjuvant therapy, patients undergo cervical mediastinoscopy to assess lymph nodes those with negative results proceed to surgery involving lung resection and lymph node removal. During the study, patients will be closely monitored through about 12 weeks of treatment and surgical assessment, followed by follow-up visits lasting up to five years after surgery. Researchers will evaluate outcomes such as lymph node downstaging, surgical success, pathological response, survival rates, and adverse events. The study includes various assessments like imaging scans, pathology reviews, and safety monitoring to track treatment effects and patient health over time.

CONDITIONS

Brief Title

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Research Team

H

Hong Yang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here